atazanavir brands

10 registered brands containing atazanavir in Kenya.

Atazanavir 2D chemical structure

2D structure

Atazanavir

PubChem CID 148192

Molecular formula: C38H52N6O7

Atazanavir selectively inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells by binding to the active site of HIV-1 protease, thus preventing the formation of mature virions. Atazanavir is not active against HIV-2. Atazanavir is an azapeptide HIV-1 protease inhibitor. The compound selectively inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, thus preventing formation of mature virions. BMS-232632 is an azapeptide human immunodeficiency virus type 1 (HIV-1) protease (Prt) inhibitor that exhibits potent anti-HIV activity with a 50% effective concentration (EC(50)) of 2.6 to 5.3 nM and an EC(90) of 9 to 15 nM in cell culture. Proof-of-principle studies indicate that BMS-232632 blocks the cleavage of viral precursor proteins in HIV-infected cells, proving that it functions as an HIV Prt inhibitor. Comparative studies showed that BMS-232632 is generally more potent than the five currently approved HIV-1 Prt inhibitors. Furthermore, BMS-232632 is highly selective for HIV-1 Prt and exhibits cytotoxicity only at concentrations 6,500- to 23, 000-fold higher than that required for anti-HIV activity. To assess the potential of this inhibitor when used in combination with other antiretrovirals, BMS-232632 was evaluated for anti-HIV activity in two-drug combination studies. Combinations of BMS-232632 with either stavudine, didanosine, lamivudine, zidovudine, nelfinavir, indinavir, ritonavir, saquinavir, or amprenavir in HIV-infected peripheral blood mononuclear cells yielded additive to moderately synergistic antiviral effects. Importantly, combinations of drug pairs did not result in antagonistic anti-HIV activity or enhanced cytotoxic effects at the highest concentrations used for antiviral evaluation. Our results suggest that BMS-232632 may be an effective HIV-1 inhibitor that may be utilized in a variety of different drug combinations.

Source: PubChem (NCBI) · compound 148192

Product Manufacturer Status Country
ANZAVIR-R TABLETS
ATAZANAVIR SULFATE EQUIVALENT TO ATAZANAVIR 300MG RITONAVIR USP 100MG
Surgilinks Registered Kenya
ATAVAZ
EACH FILM COATED TABLETS CONTAINS: ATAZANAVIR SULFATE … EQUIVALENT TO ATAZANAVIR 300 MG; RITONAVIR USP…. .100 MG
Sun Pharma Registered Kenya
ATAZANAVIR (AS SULFATE)/ RITONAVIR TABLETS 300 MG/ 100 MG
300 MG/ 100 MG
Sai Pharmaceuticals Registered Kenya
ATAZANAVIR SULFATE AND RITONAVIR TABLETS 300MG AND 100MG
ATAZANAVIR SULFATE AND RITONAVIR TABLETS 300MG AND 100MG RESPECTIVELY.
Nairobi Enterprises Registered Kenya
ATAZANAVIR SULFATE AND RITONAVIR TABLETS 300MG/100 MG
EACH FILM-COATED TABLET CONTAINS 300 MG OF ATAZANAVIR AS ATAZANAVIR SULFATE AND 100 MG OF RITONAVIR USP.
Unisel Registered Kenya
ATAZOR 150MG CAPS
150 MG
Lazor Pharmaceuticals Registered Kenya
ATAZOR 200MG CAPS
200MG
Lazor Pharmaceuticals Registered Kenya
ATAZOR 300MG CAPSULES
300 MG
Lazor Pharmaceuticals Registered Kenya
ATAZOR-100 TABLET
100MG
Lazor Pharmaceuticals Registered Kenya
ATAZOR-R TABLETS
ATAZANAVIR SULPHATE 300MG & RITONAVIR 100MG / TABLET
Lazor Pharmaceuticals Registered Kenya